http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020234789-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6676c6f1f8b0f8b0818825b695d29ef9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-11 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9d509d1436a95b92ef81087f320d6c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f56b45bf9188e0a3e759e951583258c |
| publicationDate | 2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020234789-A1 |
| titleOfInvention | A formulation of vanillic acid to enhance the platelet count during drug-induced thrombocytopenia |
| abstract | The invention discloses a formulation of vanillic acid to enhance the platelets count during drug-induced thrombocytopenia condition. Male Wistar rats are administered with an oral dose of hydroxyurea dissolved in phosphate buffer to induce thrombocytopenia. The thrombocytopenic male Wistar rats are further supplemented with a formulation comprising vanillic acid at the concentration of 50 mg/kg body weight of thrombocytopenic male Wistar rat dissolved in 2 ml of phosphate buffer. A single dose of the formulation is administered to each thrombocytopenic male Wistar rat until the platelet count increased. A significant increase in the platelet count was observed after 7 days. The dosage is further formulated in a pharmaceutically acceptable solid or liquid form to provide for treating various conditions leading to thrombocytopenia. |
| priorityDate | 2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.